Patents Assigned to Mei Pharma, Inc.
  • TREATMENT OF KRAS MUTANT CANCERS
    Publication number: 20240016781
    Abstract: The disclosure herein provides combination therapies for the treatment of KRAS mutant cancers. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by Formula I or a pharmaceutically acceptable salt thereof together with an additional therapeutic agent, e.g., an anticancer agent.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 18, 2024
    Applicant: MEI Pharma, Inc.
    Inventors: Sandra E. Wiley, Daniel P. Gold
  • Isoflavonoid compositions and methods for the treatment of cancer
    Patent number: 11723893
    Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: August 15, 2023
    Assignee: MEI Pharma, Inc.
    Inventor: Ofir Moreno
  • VORUCICLIB POLYMORPHS AND METHODS OF MAKING AND USING THEREOF
    Publication number: 20230167096
    Abstract: The disclosure relates to crystalline solid forms of voruciclib, including voruciclib free base and various voruciclib salts, pharmaceutical compositions containing voruciclib crystalline solid forms, and methods for treating conditions or disorders by administering pharmaceutical compositions including voruciclib crystalline solid forms.
    Type: Application
    Filed: April 11, 2020
    Publication date: June 1, 2023
    Applicant: MEI PHARMA, INC.
    Inventor: David Frank DUNCAN
  • Isoflavonoid compounds and methods for the treatment of cancer
    Patent number: 11583514
    Abstract: Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: February 21, 2023
    Assignee: MEI Pharma, Inc.
    Inventors: George Jeoffreys, Alison Johnson, Andrew Heaton, Ofir Moreno
  • (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
    Patent number: 11400097
    Abstract: Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: August 2, 2022
    Assignee: MEI Pharma, Inc.
    Inventors: S. David Brown, David J. Matthews
  • Combination therapy
    Patent number: 11351176
    Abstract: Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a CD20 inhibitor to a patient.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: June 7, 2022
    Assignee: MEI Pharma, Inc.
    Inventor: Daniel P. Gold
  • Combination therapy
    Patent number: 11304953
    Abstract: Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a PD-1 or PD-L1 inhibitor to a patient.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: April 19, 2022
    Assignee: MEI Pharma, Inc.
    Inventor: Daniel P. Gold
  • Combination therapies
    Patent number: 10980774
    Abstract: Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: April 20, 2021
    Assignees: MEI PHARMA, INC., THE SPANISH NATIONAL CANCER RESEARCH CENTRE
    Inventors: Daniel P. Gold, Miguel Quintela-Fandino
  • Isoflavonoid compositions and methods for the treatment of cancer
    Patent number: 10973799
    Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: April 13, 2021
    Assignee: MEI PHARMA, INC.
    Inventor: Ofir Moreno
  • Benzimidazole derivatives: preparation and pharmaceutical applications
    Patent number: 10736881
    Abstract: The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: August 11, 2020
    Assignee: MEI Pharma, Inc.
    Inventors: DiZhong Chen, Hong Yan Song, Eric T. Sun, Niefang Yu, Yong Zou
  • Polymorphic forms of 3-[(2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide and uses thereof
    Patent number: 10626092
    Abstract: Crystalline polymorph forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of diseases and conditions are also presented.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: April 21, 2020
    Assignee: MEI PHARMA, INC.
    Inventor: David Duncan
  • (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
    Patent number: 10603324
    Abstract: Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: March 31, 2020
    Assignee: MEI Pharma, Inc.
    Inventors: S. David Brown, David J. Matthews
  • Isoflavonoid compositions and methods for the treatment of cancer
    Patent number: 10369132
    Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: August 6, 2019
    Assignee: MEI PHARMA, INC.
    Inventor: Ofir Moreno
  • (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
    Patent number: 10335415
    Abstract: Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: July 2, 2019
    Assignee: MEI PHARMA, INC.
    Inventors: S. David Brown, David J. Matthews
  • Benzimidazole derivatives: preparation and pharmaceutical applications
    Patent number: 10201527
    Abstract: The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: February 12, 2019
    Assignee: MEI PHARMA, INC.
    Inventors: DiZhong Chen, Hong Yan Song, Eric T. Sun, Niefang Yu, Yong Zou
  • Isoflavonoid compounds and methods for the treatment of cancer
    Patent number: 10105346
    Abstract: Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: October 23, 2018
    Assignee: MEI PHARMA, INC.
    Inventors: George Jeoffreys, Alison Johnson, Andrew Heaton, Ofir Moreno
  • (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
    Patent number: 10064868
    Abstract: Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: September 4, 2018
    Assignee: MEI PHARMA, INC.
    Inventors: S. David Brown, David J. Matthews
  • Isoflavonoid compositions and methods for the treatment of cancer
    Patent number: 9981936
    Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: May 29, 2018
    Assignee: MEI Pharma, Inc.
    Inventor: Ofir Moreno
  • Benzimidazole derivatives: preparation and pharmaceutical applications
    Patent number: 9717713
    Abstract: The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: August 1, 2017
    Assignee: MEI PHARMA, INC.
    Inventors: DiZhong Chen, Hong Yan Song, Eric T. Sun, Niefang Yu, Yong Zou
  • Isoflavonoid compositions and methods for the treatment of cancer
    Patent number: 9708283
    Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: July 18, 2017
    Assignee: MEI PHARMA, INC.
    Inventor: Ofir Moreno